Fifth Circuit prepares to review telehealth mifepristone access

The Fifth Circuit is expected to consider Louisiana’s challenge to telehealth mifepristone access, including standing, nationwide remedies, and FDA authority. The Trump administration is not defending Biden-era rules but is pursuing an FDA safety review, with an October deadline that could affect access and 2026 campaign dynamics.